XBI vs. ARKG
Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
XBI and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014.
Performance
XBI vs. ARKG - Performance Comparison
Loading graphics...
XBI vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 4.76% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
ARKG ARK Genomic Revolution Multi-Sector ETF | -8.80% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
Returns By Period
In the year-to-date period, XBI achieves a 4.76% return, which is significantly higher than ARKG's -8.80% return. Over the past 10 years, XBI has outperformed ARKG with an annualized return of 9.32%, while ARKG has yielded a comparatively lower 4.69% annualized return.
XBI
- 1D
- 7.53%
- 1M
- 0.28%
- YTD
- 4.76%
- 6M
- 27.90%
- 1Y
- 58.08%
- 3Y*
- 19.00%
- 5Y*
- -1.29%
- 10Y*
- 9.32%
ARKG
- 1D
- 6.45%
- 1M
- -11.87%
- YTD
- -8.80%
- 6M
- -4.86%
- 1Y
- 27.26%
- 3Y*
- -4.22%
- 5Y*
- -21.56%
- 10Y*
- 4.69%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XBI vs. ARKG - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Return for Risk
XBI vs. ARKG — Risk / Return Rank
XBI
ARKG
XBI vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XBI | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.02 | 0.61 | +1.40 |
Sortino ratioReturn per unit of downside risk | 2.70 | 1.19 | +1.51 |
Omega ratioGain probability vs. loss probability | 1.34 | 1.13 | +0.21 |
Calmar ratioReturn relative to maximum drawdown | 3.72 | 0.82 | +2.90 |
Martin ratioReturn relative to average drawdown | 13.98 | 2.22 | +11.76 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XBI | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.02 | 0.61 | +1.40 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.04 | -0.48 | +0.44 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.29 | 0.11 | +0.18 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.36 | 0.08 | +0.28 |
Correlation
The correlation between XBI and ARKG is 0.82, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
XBI vs. ARKG - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.34%, while ARKG has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% | 0.00% | 0.00% |
Drawdowns
XBI vs. ARKG - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for XBI and ARKG.
Loading graphics...
Drawdown Indicators
| XBI | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -83.59% | +19.70% |
Max Drawdown (1Y)Largest decline over 1 year | -13.39% | -27.51% | +14.12% |
Max Drawdown (5Y)Largest decline over 5 years | -55.04% | -80.18% | +25.14% |
Max Drawdown (10Y)Largest decline over 10 years | -63.89% | -83.59% | +19.70% |
Current DrawdownCurrent decline from peak | -26.17% | -76.36% | +50.19% |
Average DrawdownAverage peak-to-trough decline | -20.91% | -35.30% | +14.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.71% | 10.16% | -6.45% |
Volatility
XBI vs. ARKG - Volatility Comparison
The current volatility for SPDR S&P Biotech ETF (XBI) is 11.60%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 13.28%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XBI | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.60% | 13.28% | -1.68% |
Volatility (6M)Calculated over the trailing 6-month period | 19.25% | 31.86% | -12.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.24% | 44.94% | -15.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.23% | 45.37% | -13.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.15% | 40.94% | -8.79% |